Major asset management and investment firms continue to adjust their stakes in Regeneron Pharmaceuticals. Northern Trust Corp holds $635.34 million in Regeneron, a substantial figure indicating strong institutional faith in the biotech firm. In terms of market performance, Regeneron's stock is down 51% from its all-time highs, attracting attention as a potential buying opportunity. Regeneron's collaboration with Sanofi on a $1 billion immunology project suggests promising developments in the pipeline. The company has seen its investments and stakes boosted by Qtron Investments, Raymond James Financial, and many others, however, there have been some reductions from entities like Ethic Inc. and Korea Investment CORP. Regarding Regeneron's product updates, the FDA has postponed key EYLEA HD approval decisions to late 2025, causing some consternation among investors. However, the company's Q2 sales grew by 29%, and it continues to confidently navigate the regulatory waters despite some hurdles.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 08 May 2025 07:00:00 GMT to Sat, 23 Aug 2025 21:10:04 GMT - Rating 2 - Innovation 1 - Information 7 - Rumor -3
